To kick off the autumn conference season, London hosted the ESC Congress, the world’s largest cardiology meeting, with over 30,000 participants. Among the many discussions, the intersection of cardiology and diabetology, particularly the use of modern glucose-lowering drugs such as SGLT2 inhibitors and GLP-1 based therapies, took centre stage.
“Cardiology and diabetology used to be separate disciplines, but now they’re merging, discussing the same peptides and the same patients,” says Tina Vilsbøll, Honorary Secretary of the EASD and speaker at the EASD/ESC Joint Symposium. This marks a shift that began with the presentation of the EMPA-REG OUTCOME trial and is now reflected in the ADA/EASD guidelines, which prioritise comorbidities rather than glucose levels. The message is clear: Precision medicine is here to stay. Vilsbøll highlights the importance of individualised therapies that consider comorbidities, body weight and personal circumstances.